Q3 2025 Maravai LifeSciences Holdings Inc Earnings Call Transcript
Key Points
- Maravai LifeSciences Holdings Inc (MRVI) reported strong growth in its biologic safety testing segment, with recurring revenue from novel monoclonal antibodies, biosimilars, and recombinant vaccines.
- The company has successfully stabilized operations and significantly reduced expenses, aiming for a $50 million reduction in annualized expenses.
- Maravai LifeSciences Holdings Inc (MRVI) launched innovative products like ModTail technology and IVT Kits, which are expected to drive future revenue growth.
- The company has secured multi-year supply agreements in its CDMO services, enhancing revenue visibility and strengthening long-term partnerships.
- Maravai LifeSciences Holdings Inc (MRVI) has a strong balance sheet with $243.6 million in cash, providing flexibility for strategic investments.
- Total revenue for Q3 2025 was $41.6 million, a significant decline from $69 million in Q3 2024.
- The nucleic acid product segment experienced a 53% year-over-year decline, primarily due to the timing of GMP product orders.
- Adjusted EBITDA was negative $10.8 million for Q3 2025, compared to a positive $16.2 million in Q3 2024.
- The company reported a GAAP net loss of $45.1 million for the third quarter of 2025.
- Revenue from China was down, indicating continued weakness in that market.
Good afternoon, everyone. Welcome to today's Maravai LifeSciences third-quarter 2025 earnings cesults conference call. (Operator Instructions) Also, today's call is being recorded. (Operator Instructions)
Now at this time, I'd like to turn things over to Ms. Deb Hart, Head of Investor Relations. Ms. Hart, please go ahead, ma'am.
Good afternoon, everyone. Thanks for joining us on our third-quarter 2025 earnings call. The press release and slides accompanying today's call are posted on our website and available at investors.maravai.com.
During today's call, management will make forward-looking statements and refer to GAAP and non-GAAP financial measures. It's possible that actual results could differ from management's expectations. We refer you to slide 3 for details on forward-looking statements and our use of non-GAAP financial measures. The press release provides reconciliation to the most directly comparable GAAP measures, and we also post a reconciling
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
